USD 2.63
↓ -0.2 (-7.07%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RMTI | -7.1 | -40.2 | -23.5 | 9.6 | 54.7 | 33.5 | -53.1 | -88.1 | -97.8 | -95.3 |
| S&P 500 | 0.0 | 0.1 | 2.9 | 10.1 | 14.6 | 35.7 | 27.8 | 93.4 | 193.5 | 33792.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RMTI |
| name | Rockwell Medical, Inc. |
| price | 2.63 |
| changes percentage | -7.07 |
| change | -0.20 |
| day low | 2.58 |
| day high | 3.04 |
| year high | 5.15 |
| year low | 1.16 |
| market cap | 81609426 |
| price avg 50 | 3.72 |
| price avg 200 | 2.26 |
| exchange | NASDAQ |
| volume | 2792701 |
| avg volume | 705065 |
| open | 3 |
| previous close | 2.83 |
| eps | -0.15 |
| pe | -17.53 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 31030200 |
| timestamp | 2024-11-13 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001041024 | |||
| revenue | 83612000 | 72810000 | 14.84 |
| gross profit | 8704000 | 4077000 | 113.49 |
| gross profit ratio | 0.1 | 0.06 | 85.91 |
| research and development expenses | 1107000 | 3119000 | -64.51 |
| operating expenses | 15374000 | 20857000 | -26.29 |
| interest income | 211000 | 33000 | 539.39 |
| interest expense | 2301000 | 1936000 | 18.85 |
| ebitda | -4694000 | -16167000 | 70.97 |
| ebitdaratio | -0.06 | -0.23 | 75.59 |
| operating income | -6670000 | -16780000 | 60.25 |
| operating income ratio | -0.08 | -0.23 | 65.39 |
| net income | -8439000 | -20578000 | 58.99 |
| net income ratio | -0.1 | -0.28 | 64.29 |
| eps | -0.36 | -2.09 | 82.78 |
Revenue Growth: revenue increased to 84 million in 2023 from 73 million in 2022 representing a change of 14.84%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 9 million in 2023 from 4 million in 2022 representing a change of 113.49%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 15 million in 2023 from 21 million in 2022 representing a change of -26.29%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -5 million in 2023 from -16 million in 2022 representing a change of 70.97%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -7 million in 2023 from -17 million in 2022 representing a change of 60.25%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -8 million in 2023 from -21 million in 2022 representing a change of 58.99%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.36 in 2023 from -0.36 in 2022 representing a change of 82.78%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2023 from 3 million in 2022 representing a change of -64.51%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001041024 | |||
| revenue | 28316000 | 25832000 | 9.62 |
| gross profit | 6239000 | 4550000 | 37.12 |
| gross profit ratio | 0.22 | 0.18 | 25.09 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 4303000 | 4035000 | 6.64 |
| interest income | 30000 | 9000 | 233.33 |
| interest expense | -302000 | 232000 | -230.17 |
| ebitda | 1936000 | 1124000 | 72.24 |
| ebitdaratio | 0.07 | 0.04 | 57.13 |
| operating income | 1936000 | 515000 | 275.92 |
| operating income ratio | 0.07 | 0.02 | 242.94 |
| net income | 1664000 | 343000 | 385.13 |
| net income ratio | 0.06 | 0.01 | 342.57 |
| eps | 0.05 | 0.01 | 460.64 |
Revenue Growth: revenue increased to 28 million in 2024Q3 from 26 million in 2024Q2 representing a change of 9.62%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 6 million in 2024Q3 from 5 million in 2024Q2 representing a change of 37.12%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 2 million in 2024Q3 from 1 million in 2024Q2 representing a change of 72.24%. The increase in EBITDA indicates improved operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to 0.05 in 2024Q3 from 0.05 in 2024Q2 representing a change of 460.64%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 4 million in 2024Q3 from 4 million in 2024Q2 representing a change of 6.64%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 2 million in 2024Q3 from 1 million in 2024Q2 representing a change of 275.92%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 2 million in 2024Q3 from 0 million in 2024Q2 representing a change of 385.13%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001041024 | |||
| total assets | 52173000 | 46635000 | 11.88 |
| total liabilities | 30882000 | 32529000 | -5.06 |
| total equity | 21291000 | 14106000 | 50.94 |
| cash and cash equivalents | 8983000 | 21492000 | -58.20 |
| short term investments | 1952000 | 11390000 | -82.86 |
| long term investments | 0 | 0 | NaN |
| total current assets | 28770000 | 35310000 | -18.52 |
| total non current assets | 23403000 | 11325000 | 106.65 |
| total current liabilities | 16637000 | 17691000 | -5.96 |
| total non current liabilities | 14245000 | 14838000 | -4.00 |
| common stock | 3000 | 1000 | 200.00 |
| retained earnings | -397198000 | -388759000 | -2.17 |
| total debt | 13439000 | 16363000 | -17.87 |
Total Assets: Total Assets increased to 52 million in 2023 from 47 million in 2022 representing a change of 11.88%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 31 million in 2023 from 33 million in 2022 representing a change of -5.06%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 21 million in 2023 from 14 million in 2022 representing a change of 50.94%. This indicates an increase in shareholders' equity.
Total Current Liabilities: Total Current Liabilities decreased to 17 million in 2023 from 18 million in 2022 representing a change of -5.96%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 200.0%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 13 million in 2023 from 16 million in 2022 representing a change of -17.87%. This indicates a reduction in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 9 million in 2023 from 21 million in 2022 representing a change of -58.2%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 2 million in 2023 from 11 million in 2022 representing a change of -82.86%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 29 million in 2023 from 35 million in 2022 representing a change of -18.52%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -397 million in 2023 from -389 million in 2022 representing a change of -2.17%. This indicates an accumulated losses.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001041024 | |||
| total assets | 57084000 | 53028000 | 7.65 |
| total liabilities | 27949000 | 29530000 | -5.35 |
| total equity | 29135000 | 23498000 | 23.99 |
| cash and cash equivalents | 12338000 | 11863000 | 4.00 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 34217000 | 29753000 | 15.00 |
| total non current assets | 22867000 | 23275000 | -1.75 |
| total current liabilities | 14178000 | 14891000 | -4.79 |
| total non current liabilities | 13771000 | 14639000 | -5.93 |
| common stock | 0 | 3000 | -100.00 |
| retained earnings | 0 | -398586000 | 100.00 |
| total debt | 11566000 | 14377000 | -19.55 |
Total Assets: Total Assets increased to 57 million in 2024Q3 from 53 million in 2024Q2 representing a change of 7.65%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 28 million in 2024Q3 from 30 million in 2024Q2 representing a change of -5.35%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 29 million in 2024Q3 from 23 million in 2024Q2 representing a change of 23.99%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 12 million in 2024Q3 from 12 million in 2024Q2 representing a change of 4.0%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 34 million in 2024Q3 from 30 million in 2024Q2 representing a change of 15.0%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 14 million in 2024Q3 from 15 million in 2024Q2 representing a change of -4.79%. This indicates a lower short-term debt burden.
Retained Earnings: Retained Earnings increased to 0 million in 2024Q3 from -399 million in 2024Q2 representing a change of 100.0%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 12 million in 2024Q3 from 14 million in 2024Q2 representing a change of -19.55%. This indicates a reduction in overall debt burden.
Common Stock: Common Stock decreased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of -100.0%. This indicates a decrease in ownership interest.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001041024 | |||
| net change in cash | -1119000 | -3178000 | 64.79 |
| operating cash flow | -9412000 | -17414000 | 45.95 |
| free cash flow | -9696000 | -17695000 | 45.20 |
| capital expenditure | -284000 | -281000 | -1.07 |
| depreciation and amortization | 1444000 | 2589000 | -44.23 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 932000 | 315000 | 195.87 |
| accounts payables | 463000 | 314000 | 47.45 |
| inventory | 1176000 | -2101000 | 155.97 |
| acquisitions net | -12361000 | 2115000 | -684.44 |
| investments in property plant and equipment | -284000 | -281000 | -1.07 |
| net cash used for investing activites | -3045000 | -2396000 | -27.09 |
| debt repayment | -3514000 | -13193000 | 73.36 |
| common stock issued | 14861000 | 15016000 | -1.03 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 11342000 | 16632000 | -31.81 |
| cash at end of period | 8983000 | 10102000 | -11.08 |
| accounts receivables | -4642000 | -346000 | -1,241.62 |
| cash at beginning of period | 10102000 | 13280000 | -23.93 |
Net Change in Cash: Net Change in Cash increased to -1 million in 2023 from -3 million in 2022 representing a change of 64.79%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -9 million in 2023 from -17 million in 2022 representing a change of 45.95%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -10 million in 2023 from -18 million in 2022 representing a change of 45.2%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2023 from 0 million in 2022 representing a change of -1.07%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to -5 million in 2023 from 0 million in 2022 representing a change of -1241.62%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Stock-Based Compensation: Stock-Based Compensation increased to 1 million in 2023 from 0 million in 2022 representing a change of 195.87%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 0 million in 2023 from 0 million in 2022 representing a change of 47.45%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001041024 | |||
| operating cash flow | 4275000 | 1442000 | 196.46 |
| free cash flow | 4700000 | 1156000 | 306.57 |
| capital expenditure | 425000 | -286000 | 248.60 |
| depreciation and amortization | 543000 | 549000 | -1.09 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 321000 | 338000 | -5.03 |
| accounts receivables | 1963000 | 254000 | 672.83 |
| accounts payables | -740000 | -1572000 | 52.93 |
| inventory | 326000 | 190000 | 71.58 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 425000 | -286000 | 248.60 |
| net cash used for investing activites | -6112000 | 1717000 | -455.97 |
| debt repayment | 0 | -138000 | 100.00 |
| common stock issued | 3630000 | 2203000 | 64.78 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 2313000 | 2065000 | 12.01 |
| net change in cash | 475000 | 5221000 | -90.90 |
| cash at end of period | 12338000 | 11863000 | 4.00 |
| cash at beginning of period | 11863000 | 6642000 | 78.61 |
Net Change in Cash: Net Change in Cash decreased to 0 million in 2024Q3 from 5 million in 2024Q2 representing a change of -90.9%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 248.6%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 2 in 2024Q3 from 0 million in 2024Q2 representing a change of 672.83%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 4 million in 2024Q3 from 1 million in 2024Q2 representing a change of 196.46%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 5 million in 2024Q3 from 1 million in 2024Q2 representing a change of 306.57%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -5.03%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2024Q3 from 2 million in 2024Q2 representing a change of 52.93%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 3.58 | 7.38 | -51.42 |
| net income per share | -0.36 | -2.09 | 82.65 |
| operating cash flow per share | -0.4 | -1.76 | 77.13 |
| free cash flow per share | -0.42 | -1.79 | 76.82 |
| cash per share | 0.47 | 3.33 | -85.93 |
| book value per share | 0.91 | 1.43 | -36.15 |
| tangible book value per share | 0.41 | 1.34 | -69.16 |
| shareholders equity per share | 0.91 | 1.43 | -36.15 |
| interest debt per share | 0.46 | 1.18 | -60.56 |
| market cap | 44080309.35 | 9965512.44 | 342.33 |
| enterprise value | 48536309.35 | 4836512.44 | 903.54 |
| pe ratio | -5.22 | -0.48 | -978.59 |
| price to sales ratio | 0.53 | 0.14 | 285.18 |
| pocfratio | -4.68 | -0.57 | -718.39 |
| pfcf ratio | -4.55 | -0.56 | -707.24 |
| pb ratio | 2.07 | 0.71 | 193.06 |
| ptb ratio | 2.07 | 0.71 | 193.06 |
| ev to sales | 0.58 | 0.07 | 773.89 |
| enterprise value over ebitda | -10.34 | -0.3 | -3,356.37 |
| ev to operating cash flow | -5.16 | -0.28 | -1,756.74 |
| ev to free cash flow | -5.01 | -0.27 | -1,731.44 |
| earnings yield | -0.19 | -2.06 | 90.73 |
| free cash flow yield | -0.22 | -1.78 | 87.61 |
| debt to equity | 0.4 | 0.69 | -41.62 |
| debt to assets | 0.16 | 0.21 | -21.24 |
| net debt to ebitda | -0.95 | 0.32 | -399.23 |
| current ratio | 1.73 | 2.0 | -13.36 |
| interest coverage | -2.9 | -8.67 | 66.56 |
| income quality | 1.12 | 0.93 | 19.63 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.15 | 0.21 | -32.41 |
| research and ddevelopement to revenue | 0.01 | 0.04 | -69.09 |
| intangibles to total assets | 0.22 | 0.02 | 1,033.57 |
| capex to operating cash flow | -0.03 | -0.02 | -86.99 |
| capex to revenue | 0.0 | 0.0 | -11.99 |
| capex to depreciation | 0.2 | 0.11 | 81.21 |
| stock based compensation to revenue | 0.01 | 0.0 | 157.65 |
| graham number | 2.73 | 8.19 | -66.72 |
| roic | -0.22 | -0.78 | 71.22 |
| return on tangible assets | -0.21 | -0.45 | 53.70 |
| graham net net | -0.38 | 0.81 | -146.99 |
| working capital | 12133000 | 17619000 | -31.14 |
| tangible asset value | 9611000 | 13185000 | -27.11 |
| net current asset value | -2112000 | 2781000 | -175.94 |
| invested capital | 34831000 | 27145000 | 28.31 |
| average receivables | 8580000 | 6086000 | 40.98 |
| average payables | 4284500 | 3896000 | 9.97 |
| average inventory | 5842500 | 4945000 | 18.15 |
| days sales outstanding | 47.59 | 31.38 | 51.66 |
| days payables outstanding | 22.0 | 21.52 | 2.24 |
| days of inventory on hand | 28.61 | 30.87 | -7.34 |
| receivables turnover | 7.67 | 11.63 | -34.06 |
| payables turnover | 16.59 | 16.96 | -2.19 |
| inventory turnover | 12.76 | 11.82 | 7.93 |
| roe | -0.4 | -1.46 | 72.83 |
| capex per share | 0.01 | 0.03 | -57.24 |
ROE: Return on Equity (ROE) increased to -0.40 on 2023-12-31 from -1.46 on 2022-12-31, representing a change of 72.83%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -5.22 on 2023-12-31 from -0.48 on 2022-12-31, representing a change of -978.59%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.73 on 2023-12-31 from 2.00 on 2022-12-31, representing a change of -13.36%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.40 on 2023-12-31 from 0.69 on 2022-12-31, representing a change of -41.62%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| RMTI | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.9 | 0.85 | 5.79 |
| net income per share | 0.05 | 0.01 | 368.22 |
| operating cash flow per share | 0.14 | 0.05 | 186.13 |
| free cash flow per share | 0.15 | 0.04 | 292.40 |
| cash per share | 0.39 | 0.39 | 0.38 |
| book value per share | 0.92 | 0.77 | 19.67 |
| tangible book value per share | 0.57 | 0.4 | 42.60 |
| shareholders equity per share | 0.92 | 0.77 | 19.67 |
| interest debt per share | 0.36 | 0.3 | 18.20 |
| market cap | 125260665.85 | 50854208.74 | 146.31 |
| enterprise value | 124488665.85 | 53368208.74 | 133.26 |
| pe ratio | 18.82 | 37.07 | -49.23 |
| price to sales ratio | 4.42 | 1.97 | 124.71 |
| pocfratio | 29.3 | 35.27 | -16.92 |
| pfcf ratio | 26.65 | 43.99 | -39.42 |
| pb ratio | 4.3 | 2.16 | 98.66 |
| ptb ratio | 4.3 | 2.16 | 98.66 |
| ev to sales | 4.4 | 2.07 | 112.80 |
| enterprise value over ebitda | 64.3 | 47.48 | 35.43 |
| ev to operating cash flow | 29.12 | 37.01 | -21.32 |
| ev to free cash flow | 26.49 | 46.17 | -42.63 |
| earnings yield | 0.01 | 0.01 | 96.96 |
| free cash flow yield | 0.04 | 0.02 | 65.06 |
| debt to equity | 0.4 | 0.38 | 4.05 |
| debt to assets | 0.2 | 0.17 | 19.85 |
| net debt to ebitda | -0.4 | 2.24 | -117.83 |
| current ratio | 2.41 | 2.0 | 20.79 |
| interest coverage | -6.41 | 2.22 | -388.79 |
| income quality | 2.48 | 5.06 | -50.93 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.13 | 0.13 | -5.39 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.2 | 0.22 | -8.23 |
| capex to operating cash flow | 0.1 | 0.2 | -49.88 |
| capex to revenue | 0.02 | 0.01 | 35.57 |
| capex to depreciation | 0.78 | 0.52 | 50.24 |
| stock based compensation to revenue | 0.01 | 0.01 | -13.36 |
| graham number | 1.05 | 0.44 | 136.71 |
| roic | 0.05 | 0.02 | 199.83 |
| return on tangible assets | 0.04 | 0.01 | 340.72 |
| graham net net | -0.19 | -0.22 | 12.16 |
| working capital | 20039000 | 14862000 | 34.83 |
| tangible asset value | 17869000 | 12094000 | 47.75 |
| net current asset value | 6268000 | 223000 | 2,710.76 |
| invested capital | 43734000 | 37411000 | 16.90 |
| average receivables | 9863000 | 10967000 | -10.07 |
| average payables | 2977000 | 4133000 | -27.97 |
| average inventory | 5885500 | 5978000 | -1.55 |
| days sales outstanding | 28.24 | 37.77 | -25.22 |
| days payables outstanding | 10.63 | 14.15 | -24.91 |
| days of inventory on hand | 24.0 | 24.88 | -3.52 |
| receivables turnover | 3.19 | 2.38 | 33.72 |
| payables turnover | 8.47 | 6.36 | 33.18 |
| inventory turnover | 3.75 | 3.62 | 3.65 |
| roe | 0.06 | 0.01 | 291.27 |
| capex per share | 0.01 | 0.01 | 43.42 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 18.82 on 2024-09-30 Q3 from 37.07 on 2024-06-30 Q2, representing a change of -49.23%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.41 on 2024-09-30 Q3 from 2.00 on 2024-06-30 Q2, representing a change of 20.79%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.40 on 2024-09-30 Q3 from 0.38 on 2024-06-30 Q2, representing a change of 4.05%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-13 07:25:12
Despite a 39% stock drop yesterday, Rockwell Medical's strong Q3 results and upcoming catalyst provide a solid buying opportunity for risk-takers. The stock's dip was due to reduced orders from its largest customer, but Rockwell is diversifying its customer base and entering the at-home dialysis market. Strategic initiatives, including new supply contracts and product line growth, are expected to mitigate revenue reductions and generate future growth.
Sentiment: Positive
Publish Date: 2024-11-12 11:30:03
Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President of Finance Conference Call Participants Anthony Venditti - Maxim Group Operator Good morning and welcome to Rockwell Medical's Third Quarter 2024 Results Conference Call and Webcast. Please note, this event is being recorded.
Sentiment: Neutral
Publish Date: 2024-11-12 08:10:17
Rockwell Medical (RMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.07 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-12 06:00:00
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced financial and operational results for the three and nine months ended September 30, 2024.
Sentiment: Neutral
Publish Date: 2024-11-08 06:00:00
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--UPDATED Q3'24 EARNINGS DATE: Rockwell Medical will release its third quarter 2024 financial and operational results on November 12, 2024.
Sentiment: Positive
Publish Date: 2024-10-31 11:56:10
Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.
Sentiment: Positive
Publish Date: 2024-10-18 11:36:10
This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.
Sentiment: Positive
Publish Date: 2024-10-17 13:01:15
Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sentiment: Neutral
Publish Date: 2024-10-14 06:00:00
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024.
Sentiment: Positive
Publish Date: 2024-09-20 10:16:10
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sentiment: Positive
Publish Date: 2024-09-18 13:31:12
RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.
Sentiment: Positive
Publish Date: 2024-09-18 06:00:00
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Great Place to Work and Fortune magazine selected Rockwell Medical for the 2024 Fortune Best Workplaces in Manufacturing and Production List.
Sentiment: Negative
Publish Date: 2024-09-15 14:06:17
Rockwell develop concentrates for hemodialysis, which is a process that seeks to artificially replace kidney function in patients with chronic failure. Despite being a critical product, there's currently no large competitor dominating the category and the company is a leader. After years of constant CEO turnover and poor results, Mr. Mark Strobeck has turned around and has already reached its first profitable quarter ever.
Sentiment: Positive
Publish Date: 2024-09-09 13:00:29
Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sentiment: Positive
Publish Date: 2024-09-09 09:51:16
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Sentiment: Positive
Publish Date: 2024-09-04 10:16:04
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sentiment: Positive
Publish Date: 2024-08-19 10:15:45
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
